{"id":888227,"date":"2025-09-22T08:45:06","date_gmt":"2025-09-22T12:45:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-showcases-phase-4-data-demonstrating-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-treatment-effects-and-real-world-evidence-at-world-sleep-and-ps\/"},"modified":"2025-09-22T08:45:06","modified_gmt":"2025-09-22T12:45:06","slug":"jazz-pharmaceuticals-showcases-phase-4-data-demonstrating-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-treatment-effects-and-real-world-evidence-at-world-sleep-and-ps","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-showcases-phase-4-data-demonstrating-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-treatment-effects-and-real-world-evidence-at-world-sleep-and-ps\/","title":{"rendered":"Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n 20 abstracts presented across World Sleep and Psych Congresses showcase Jazz’s leadership in sleep medicine<\/i>\n <\/p>\n

\n Novel results from the Phase 4 DUET trial underscore the significance of appropriate treatment options in adults with narcolepsy or idiopathic hypersomnia<\/i>\n <\/p>\n

\n For U.S. media and investors only<\/i>\n <\/p>\n

\n
\n DUBLIN<\/span>
\n <\/span>, Sept. 22, 2025<\/span><\/span> \/PRNewswire\/ — Jazz\u00a0Pharmaceuticals\u00a0plc\u00a0(Nasdaq:\u00a0JAZZ) today\u00a0announced new real-world evidence and Phase 4\u00a0data reinforcing the value of Xywav\u00ae<\/sup> (calcium, magnesium, potassium, and sodium oxybates) oral solution treatment outcomes in adults with narcolepsy or idiopathic hypersomnia (IH) were presented at World Sleep 2025, held in Singapore<\/span> from September 5-10, 2025<\/span>, as well as the 38th<\/sup> annual Psych Congress, held in San Diego<\/span> from September 17-21, 2025<\/span>. Notable Phase 4 data included new results from the DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial, showing treatment effects of low-sodium Xywav <\/i>on daytime and nighttime symptoms of narcolepsy or IH. The DUET trial is a Phase 4, prospective, single-arm, open-label study to assess the effect of Xywav <\/i>treatment on excessive daytime sleepiness, polysomnography parameters, and functional outcomes in adults with narcolepsy or IH.<\/p>\n

“These new DUET data presented by Jazz continue to show the importance of measuring and understanding the impact of treatment in both daytime and nighttime symptoms, as well as other functional outcomes in people living with narcolepsy or idiopathic hypersomnia,” said Logan Schneider<\/span>, MD, adjunct clinical associate professor of sleep medicine, Stanford Sleep Center and Consultant Neurologist, Standford\/VA Alzheimer’s Center. “These results further reflect the positive implications that an appropriate treatment can have on patients’ sleep outcomes, holistic health and their daily functioning.”<\/p>\n

“We are leveraging both the power of Phase 4 clinical trials and real-world evidence to provide clinically meaningful, high-quality research for the global sleep community, which informs the health complexities of people living with narcolepsy and idiopathic hypersomnia,” said Kelvin Tan, MB BCh, MRCPCH, chief medical affairs officer of Jazz Pharmaceuticals. “These robust data continue to expand our understanding of sleep disorders and the challenges patients living with these conditions face while further reinforcing the value of low-sodium Xywav<\/i> treatment.”<\/p>\n

Presentation highlights include:<\/p>\n